BioAdvance News iView Therapeutics Portfolio News

iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease

By WebmasterJanuary 30, 2023November 1st, 2024No Comments

iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease

See more here

Previous PostAnnovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
Next PostStrados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study

iVIEW Therapeutics announces a successful pre-IND meeting with FDA and Received its Full Agreement on Development Plans for IVW-1001, a Novel Treatment for Dry Eye Disease

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostAnnovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Next PostStrados Labs Forms Collaboration with Boehringer Ingelheim for its Idiopathic Pulmonary Fibrosis (IPF) Pilot Study